<DOC>
	<DOCNO>NCT00813046</DOCNO>
	<brief_summary>The purpose study determine whether oral administration grass pollen peptides treat allergic rhinitis safe well tolerate .</brief_summary>
	<brief_title>Safety Tolerance Study Grass Pollen-derived Peptides Treat Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>Age 18 50 year The subject good physical mental health accord his/her medical history , vital sign , clinical status Male nonpregnant , nonlactating female A history seasonal allergic rhinoconjunctivitis ( SAR ) grass pollen season least last two year A positive skin prick test grasspollen mixture Specific IgE grass pollen ( RAST class 2 IgE &gt; 0.7 kU/l ) Asymptomatic perennial inhalant allergens Subjects current past immunotherapy SAR Subjects require controller medication asthma ( bronchodilator nebulised drug local systemic corticosteroid ) Documented evidence acute significant chronic sinusitis ( determine individual investigator ) Subjects history food allergy consecutive anaphylaxis Subjects history hepatic renal disease Subject malignant disease , autoimmune disease Female subject pregnant , lactating , childbearing potential protected pregnancy sufficiently reliable method ( OCs , IUD ) . Females unable bear child must documentation ( i.e . tubal ligation , hysterectomy , post menopausal [ define minimum one year since last menstrual period ] ) Any chronic disease , may impair subject 's ability participate trial ( i.e . severe congestive heart failure , active gastric duodenal ulcer , uncontrolled diabetes mellitus , etc… ) Subjects clinically relevant abnormal QTc interval ECG : QTc &gt; 450 m man &gt; 470 ms woman Subjects require betablockers medication Chronic use concomitant medication would affect assessment effectiveness study medication ( e.g . tricyclic antidepressant ) Subject febrile illness ( &gt; 37.5°C , oral ) A know positive serology HIV1/2 , HBs antigen antiHCV antibodies The subject immunocompromised medication illness , receive vaccine , corticoid immunosuppressive medication within 1 month study entry Receipt blood blood derivative past 6 month precede study entry Regular consumption corticoid ( oral , topic nasal ) antihistaminic drug within 4 week precede study , consumption corticoid ( oral , topic nasal ) antihistaminic drug within 1 week precede study Use longacting antihistamine Any condition could incompatible protocol understand compliance Subjects forfeit freedom administrative legal award guardianship , Participation another clinical trial and/or treatment experimental drug within 1 month study start A history hypersensitivity excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>